193 related articles for article (PubMed ID: 38528312)
1. A Canadian Simulation Model for Major Depressive Disorder: Study Protocol.
Ghanbarian S; Wong GWK; Bunka M; Edwards L; Cressman S; Conte T; Peterson S; Vijh R; Price M; Schuetz C; Erickson D; Riches L; Landry G; McGrail K; Austin J; Bryan S
Pharmacoecon Open; 2024 May; 8(3):493-505. PubMed ID: 38528312
[TBL] [Abstract][Full Text] [Related]
2. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
[TBL] [Abstract][Full Text] [Related]
3. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomic Testing for Major Depression: A Qualitative Study of the Perceptions of People with Lived Experience and Professional Stakeholders.
Slomp C; Morris E; Edwards L; Hoens AM; Landry G; Riches L; Ridgway L; Bryan S; Austin J
Can J Psychiatry; 2023 Jun; 68(6):436-452. PubMed ID: 36437757
[TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of pharmacogenomic-guided treatment for major depression.
Ghanbarian S; Wong GWK; Bunka M; Edwards L; Cressman S; Conte T; Price M; Schuetz C; Riches L; Landry G; Erickson D; McGrail K; Peterson S; Vijh R; Hoens AM; Austin J; Bryan S
CMAJ; 2023 Nov; 195(44):E1499-E1508. PubMed ID: 37963621
[TBL] [Abstract][Full Text] [Related]
7. Patient perspectives on pharmacogenomic (PGx) testing for antidepressant prescribing in primary care: a qualitative description study.
Cernat A; Samaan Z; Abelson J; Ramdyal A; Shaikh H; Vanstone M
J Community Genet; 2024 Jun; 15(3):293-309. PubMed ID: 38587601
[TBL] [Abstract][Full Text] [Related]
8. Behavioural modification interventions for medically unexplained symptoms in primary care: systematic reviews and economic evaluation.
Leaviss J; Davis S; Ren S; Hamilton J; Scope A; Booth A; Sutton A; Parry G; Buszewicz M; Moss-Morris R; White P
Health Technol Assess; 2020 Sep; 24(46):1-490. PubMed ID: 32975190
[TBL] [Abstract][Full Text] [Related]
9. Right care, first time: a highly personalised and measurement-based care model to manage youth mental health.
Hickie IB; Scott EM; Cross SP; Iorfino F; Davenport TA; Guastella AJ; Naismith SL; Carpenter JS; Rohleder C; Crouse JJ; Hermens DF; Koethe D; Markus Leweke F; Tickell AM; Sawrikar V; Scott J
Med J Aust; 2019 Nov; 211 Suppl 9():S3-S46. PubMed ID: 31679171
[TBL] [Abstract][Full Text] [Related]
10. Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders: A Health Technology Assessment.
Health Quality Ontario
Ont Health Technol Assess Ser; 2019; 19(6):1-199. PubMed ID: 30873251
[TBL] [Abstract][Full Text] [Related]
11. The Effectiveness of Integrated Care Pathways for Adults and Children in Health Care Settings: A Systematic Review.
Allen D; Gillen E; Rixson L
JBI Libr Syst Rev; 2009; 7(3):80-129. PubMed ID: 27820426
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
13. Study design and implementation of the PRecision Medicine In MEntal health Care (PRIME Care) Trial.
Oslin DW; Chapman S; Duvall SL; Gelernter J; Ingram EP; Kranzler HR; Lehmann LS; Lynch JA; Lynch KG; Pyne JM; Shih MC; Stone A; Thase ME; Wray LO
Contemp Clin Trials; 2021 Feb; 101():106247. PubMed ID: 33316457
[TBL] [Abstract][Full Text] [Related]
14. Repetitive transcranial magnetic stimulation for the treatment of major depressive disorder: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2004; 4(7):1-98. PubMed ID: 23074457
[TBL] [Abstract][Full Text] [Related]
15. Core discrete event simulation model for the evaluation of health care technologies in major depressive disorder.
Vataire AL; Aballéa S; Antonanzas F; Roijen LH; Lam RW; McCrone P; Persson U; Toumi M
Value Health; 2014 Mar; 17(2):183-95. PubMed ID: 24636376
[TBL] [Abstract][Full Text] [Related]
16. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(25):1-49. PubMed ID: 23074403
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
